Dark

Check out our Dark Pool Levels

BGNE
BeiGene, Ltd.
stock NASDAQ

Inactive

Dec 31, 2024

184.71USD+0.490%(+0.90)331,631

Pre-market

0.00USD-100.000%(-183.81)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 28, 2022

08:21AM EST The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron Benzinga

Jan 26, 2022

01:13PM EST New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 Bamboo Works Special Report Benzinga

Jan 25, 2022

12:17PM EST Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies Benzinga

Jan 20, 2022

08:28AM EST The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug Benzinga

Jan 19, 2022

07:40AM EST The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data Benzinga

Jan 18, 2022

08:59AM EST Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $360 Benzinga

Dec 20, 2021

06:32AM EST Novartis Inks Option, Collaboration And License Agreement With BeiGene For Ociperlimab RTTNews

06:16AM EST BeiGene Expands Collaboration With Novartis To Develop And Commercialize BeiGene's TIGIT Inhibitor And Market Five Novartis Oncology Medicines In China Broad Markets Benzinga

Dec 14, 2021

04:46AM EST Nanjing Leads Biolabs and BeiGene Announced Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China Benzinga

Dec 13, 2021

11:10PM EST Nanjing Leads Biolabs And BeiGene Announce Worldwide License And Collaboration Agreement For LBL-007 Anti-LAG-3 Antibody RTTNews

11:00PM EST Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China Business Wire

Dec 10, 2021

07:58AM EST BeiGene Unveils Results From Late-Stage Tislelizumab In Nasopharyngeal Cancer Benzinga

07:50AM EST The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares Benzinga

Dec 9, 2021

09:47PM EST Zymeworks Announces Expansion Of Zanidatamab Pivotal Trial In Asia In Collaboration With BeiGene And Associated $8M Milestone Payment Benzinga

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

08:41AM EST Direxion Launches mRNA ETF (MSGR) PR Newswire

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 3, 2021

09:20AM EST BeiGene - EUSA Pharma's Siltuximab Approved In China For Multicentric Castleman Disease Benzinga

07:40AM EST The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering Benzinga

12:40AM EST BeiGene, EUSA Pharma Unveil China's NMPA Approval Of SYLVANT For Idiopathic Multicentric Castleman Disease RTTNews

Dec 2, 2021

11:00PM EST BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA(r) (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib Business Wire

11:00PM EST BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT(r) (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease Business Wire

Nov 30, 2021

04:49PM EST BeiGene Prices IPO On STAR Market Of Shanghai Stock Exchange At HK$234.89/Share Benzinga

09:08AM EST BeiGene Announces Pricing Of US$3.5 Bln IPO On STAR Market Of Shanghai Stock Exchange In China RTTNews

09:00AM EST BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China Business Wire

Nov 24, 2021

07:32AM EST The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension Benzinga

05:45AM EST BeiGene's Brukinsa Approved In Europe For Rare Type Of Blood Cancer Benzinga

Nov 23, 2021

05:07PM EST BeiGene Announces Approval of BRUKINSA In European Union For Treatment Of Adults With Waldenstrm's Macroglobulinemia Benzinga

08:16AM EST BeiGene Highlights Launch Of Its IPO On Science, Technology Innovation Board Of China's Shanghai Stock Exchange Benzinga

Nov 22, 2021

07:09AM EST BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339 Benzinga

Nov 5, 2021

09:31AM EDT BeiGene Q3 ADS $(4.46) Up From $(4.81) YoY, Sales $206.40M Up From $91.08M YoY Benzinga

Oct 20, 2021

07:14AM EDT BeiGene And Nanolek Announce Approval In Russia For BRUKINSA For Treatment Of Patients With Relapsed Or Refractory Mantle Cell Lymphoma Benzinga

Oct 14, 2021

06:25AM EDT SVB Leerink Maintains Outperform on BeiGene, Lowers Price Target to $414 Benzinga

Oct 12, 2021

10:48AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 Benzinga

06:44AM EDT Bernstein Initiates Coverage On BeiGene with Outperform Rating, Announces Price Target of $431 Benzinga

Oct 11, 2021

10:25AM EDT BeiGene Late Sunday Reported Its BRUKINSA Approved In Australia For Treatment Of Adults With Mantle Cell Lymphoma Who Have Received At Least 1 Prior Therapy Benzinga

Oct 7, 2021

04:06PM EDT BeiGene Reports Regulatory Approvals In Australia For BRUKINSA For Treatment Of Patients With Waldenstrom's Macroglobulinemia Benzinga

Sep 17, 2021

02:17PM EDT Why BeiGene Shares Are Rising Benzinga

08:04AM EDT BeiGene Reports Positive CHMP Opinion For BRUKINSA For Treatment Of Adults With Waldenstrom's Macroglobulinemia Benzinga

05:31AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.10 A.M. EDT). RTTNews

05:02AM EDT BeiGene CEO John Oyler Reported Sale of 411,838 Shares in a Form 4 Filing on Thursday Benzinga

Sep 16, 2021

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

07:08AM EDT BeiGene Announces The US FDA Has Granted BRUKINSA Accelerated Approval In Relapsed Or Refractory Marginal Zone Lymphoma Benzinga

Sep 13, 2021

05:10AM EDT BeiGene Announced FDA Acceptance of Biologics License Application for Tislelizumab, Filed in Collaboration with Novartis, in Esophageal Squamous Cell Carcinoma Benzinga

01:48AM EDT BeiGene Ltd. (BGNE) said Monday that the U.S. Food and Drug Administration accepted for review a Biologics License Application or BLA for its anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma or ESCC after prior systemic therapy. RTTNews

01:39AM EDT BeiGene Announces FDA Acceptance For Tislelizumab BLA In Esophageal Squamous Cell Carcinoma RTTNews

Sep 2, 2021

09:37AM EDT BeiGene's Brukinsa Scores FDA Approval For Rare Blood Cancer Indication Benzinga

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

02:22PM EDT BeiGene Shares Quiet Following FDA AccessData.gov Listing Co. Received Supplemental Approval From FDA For Brukinsa Benzinga

02:21PM EDT BeiGene Shares Quiet Following Report Co. Received Supplemental Approval From FDA For Brukinsa Benzinga

Aug 23, 2021

06:00AM EDT A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises Over 3% Benzinga

Aug 22, 2021

07:29PM EDT BeiGene Announced Acceptance of Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer Benzinga

Aug 18, 2021

04:41AM EDT BeiGene: Swissmedic Begins Formal Review Of MAA For RTTNews

04:19AM EDT BeiGene : Swissmedic Accepts Marketing Application For BRUKINSA In Waldenstrm's Macroglobulinaemia RTTNews

Aug 17, 2021

10:09AM EDT BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China Benzinga

07:12AM EDT BeiGene And EUSA Pharma Announce China NMPA Approval Pf QARZIBA For Patients With High-Risk Neuroblastoma Benzinga

Aug 16, 2021

08:29AM EDT Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $407 Benzinga

Aug 5, 2021

05:46PM EDT BeiGene Q2 EPS $(5.23) Down From $(4.31) YoY, Sales $149.99M Up From $65.64M YoY Benzinga

Aug 3, 2021

07:27AM EDT BeiGene Announces Plans To Build New Manufacturing, Clinical R&D Center At Princeton West Innovation Park In Hopewell, New Jersey Benzinga

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

07:43AM EDT BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients Benzinga

Jul 26, 2021

09:39AM EDT BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma Benzinga

07:10AM EDT BeiGene Announces Canadian Approval of BRUKINSA for the Treatment of Patients with Mantle Cell Lymphoma Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

06:16AM EDT BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

11:30AM EDT PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer Benzinga

07:05AM EDT PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors Benzinga

Jun 30, 2021

08:30AM EDT Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors GlobeNewswire Inc

Jun 21, 2021

06:03AM EDT A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street Benzinga

Jun 18, 2021

04:31PM EDT BeiGene Announces China NMPA Approval of BRUKINSA for the Treatment of Patients with Relapsed or Refractory Waldenstrm's Macroglobulinemia Benzinga

Jun 17, 2021

07:04AM EDT BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer Benzinga

Jun 14, 2021

07:17AM EDT SVB Leerink Maintains Outperform on BeiGene, Raises Price Target to $417 Benzinga

Jun 11, 2021

10:15AM EDT BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica Benzinga

Jun 9, 2021

08:35AM EDT BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer Benzinga

07:06AM EDT Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer Cell Therapies; Shoreline To Receive Upfront Payment Of $45M And Is Eligible For Addition Milestone Payments Benzinga

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 7, 2021

05:01PM EDT BeiGene Reports Acceptance Of A Supplemental Biologics License Application In China For Tisleilizumab In Microsatellite Instability-High, Mismatch Repair-Deficient Solid Tumors Benzinga

Jun 4, 2021

09:10AM EDT BeiGene Presents Clinical Data From 2 Phase 2 Trials Of Pamiparib At 2021 ASCO Meeting Benzinga

Jun 3, 2021

07:59AM EDT Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $409 Benzinga

06:31AM EDT Zhongchao Inc. Announces the On-Going One-Year Leukemia Education Project with Bethune Foundation and BeiGene Shanghai Benzinga

May 21, 2021

08:21AM EDT BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer Benzinga

07:01AM EDT BeiGene Reports Topline Results From Phase 3 Trial Of Tislelizumab In Combo With Chemo For First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer: Met Primary Endpoint Benzinga

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

08:06AM EDT BeiGene's Brukinsa US Application For Expanded Use Under FDA Review Benzinga

07:02AM EDT BeiGene Announces FDA Acceptance And Priority Review Of Supplemental New Drug Application For BRUKINSA In Marginal Zone Lymphoma Benzinga

May 10, 2021

07:48AM EDT Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $357 Benzinga

May 7, 2021

07:32AM EDT BeiGene Earlier Announces China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer Benzinga

May 6, 2021

04:55PM EDT BeiGene Q1 EPS $0.69 Up From $(4.70) YoY, Sales $106.10M Up From $52.06M YoY Benzinga

Apr 28, 2021

01:19PM EDT BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies Benzinga

01:19PM EDT BeiGene's Brukinsa On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies Benzinga

07:27AM EDT BeiGene Reports BRUKINSA Demonstrated Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia Benzinga

07:00AM EDT BRUKINSA(r) (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia Business Wire

Apr 12, 2021

01:33PM EDT BeiGene Says Presents Interim Analysis Results Of RATIONALE 303 Trial Of Tislelizumab In Second- or Third-Line Non-Small Cell Lung Cancer At AACR Annual Meeting 2021; Says Global Phase 3 Trial Achieved Primary Endpoint Benzinga

Apr 11, 2021

04:24PM EDT BeiGene Announced Clinical Data on Sitravatinib in Combination with Tislelizumab Showed Preliminary Antitumor Activity in Patients With Unresectable or Metastatic Melanoma Refractory or Resistant to Pd-1/l1 Inhibitors and Platinum-resistant Ovarian Cancer at AACR 2021 Benzinga

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Apr 8, 2021

09:22AM EDT BeiGene Wednesday Announced First Commercial Manufacturing Approval For Co's Biologics Facility In Guangzhou, China Benzinga

08:29AM EDT BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study Benzinga

07:08AM EDT BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress; Co. Reports 'Trial did not meet the co-primary efficacy endpoints; no new safety signals identified' Benzinga

07:02AM EDT BeiGene Launches BRUKINSA in Canada for Patients with Waldenstrm's Macroglobulinemia Benzinga

Mar 30, 2021

10:55AM EDT BeiGene Total Revenues For Year Decreased 27.9% To ~$308.9M; FY 2020 Net Loss Attributable $1.6B Benzinga

08:39AM EDT BeiGene Appoints Julia Wang CFO Benzinga

Mar 24, 2021

07:51AM EDT Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor Study Benzinga

Mar 17, 2021

06:53AM EDT 111, Inc. Enters Agreement With BeiGene To Cooperate On An 'Internet + Medicine & Healthcare' Benzinga

Mar 10, 2021

04:39PM EST BeiGene To Present Data At American Association For Cancer Research Apr. 11, 12 Benzinga

07:02AM EST BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 Benzinga

Mar 5, 2021

08:37AM EST BeiGene Says Co Granted Acceptance Of Supplemental Biologics License Application In China For Tislelizumab In Second- Or Third-Line Non-Small Cell Lung Cancer Benzinga

Mar 2, 2021

07:16AM EST Health Canada Approves BRUKINSA for the Treatment of Waldenstrm's Macroglobulinemia Benzinga

Feb 26, 2021

06:41AM EST Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy Benzinga

Feb 25, 2021

05:07PM EST BeiGene Q4 EPS $(5.20) Up From $(6.39) YoY, Sales $100.10M Up From $56.89M YoY Benzinga

Feb 18, 2021

11:52AM EST Cowen & Co. Maintains Outperform on BeiGene, Raises Price Target to $429 Benzinga

Feb 17, 2021

05:02PM EST Boston Immune Technologies And Therapeutics And BeiGene Enter Into An Exclusive Option And License Agreement To Develop Novel TNFR2 Antagonists; BITT To Receive $16.6M In Upfront Payments And Near-Term Milestones, Eligible For Up To $105M In Milestones Benzinga

09:33AM EST BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review Benzinga

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

07:13AM EST BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenstrm's Macroglobulinemia Benzinga

Jan 27, 2021

05:45PM EST BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma Business Wire

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 25, 2021

07:02AM EST EUSA Pharma And BeiGene Announce Acceptance Of A Biologics License Application For SYLVANT In China Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 19, 2021

09:06AM EST Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $375 Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

05:55AM EST Beigene Announced China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer Benzinga

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

Jan 11, 2021

09:13PM EST China-based biotechnology companyBeiGene Ltd. (BGNE) said that it will collaborate with Novartis to develop, manufacture and commercialize BeiGene's cancer drug tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. RTTNews

04:33PM EST BeiGene Announces Collaboration with Novartis to Develop & Commercialize Anti-PD-1 Antibody Tislelizumab; Beigene To Receive $650M Upfront Payment And Is Eligible To Receive Up To $1.55B In Potential Regulatory And Sales Milestone Payments Plus Royalties Benzinga

07:28AM EST Strand Therapeutics And BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand's Next-Generation, Multi-Functional mRNA Technology; Strand To Receive $5M Upfront And Is Eligible To Receive $28M In Near-Term Payments Benzinga

07:27AM EST Strand Therapeutics And BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand's Next-Generation, Multi-Functional mRNA Technology; Strand To Receive $5M Upfront And Is Eligible To Receive $28M Benzinga

Dec 28, 2020

05:36AM EST BeiGene Announced Inclusion of tislelizumab, BRUKINSA XGEVA in China National Reimbursement Drug List Benzinga

Dec 8, 2020

10:54AM EST Ladenburg Thalmann Upgrades BeiGene to Buy, Announces $278 Price Target Benzinga

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 7, 2020

10:12AM EST BeiGene Presents Clinical Data On BRUKINSA In B-Cell Malignancies, Waldenstrm's Macroglobulinemia At ASH Benzinga

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Dec 1, 2020

04:17PM EST BeiGene Reports ~1.51M ADS Offering Benzinga

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

08:23AM EST 10 Biggest Price Target Changes For Thursday Benzinga

06:36AM EST SVB Leerink Maintains Outperform on BeiGene, Raises Price Target to $327 Benzinga

Nov 17, 2020

07:04AM EST BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis Benzinga

Nov 11, 2020

07:48AM EST Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $310 Benzinga

Nov 9, 2020

07:36AM EST EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA (Dinutuximab Beta) in China Benzinga

Nov 6, 2020

10:39AM EST SVB Leerink Maintains Outperform on BeiGene, Raises Price Target to $240 Benzinga

09:31AM EST Benzinga's Top Upgrades, Downgrades For November 6, 2020 Benzinga

06:08AM EST Piper Sandler Downgrades BeiGene to Underweight, Announces $185 Price Target Benzinga

Nov 5, 2020

05:15PM EST BeiGene Q3 EPS $(4.81) Up From $(5.11) YoY, Sales $91.08M Up From $50.14M YoY Benzinga

09:05AM EST BeiGene Highlights Presentation Of Data On BRUKINSA, Tislelizumab At Upcoming American Society Of Hematology Dec. 5-7 Benzinga

Oct 13, 2020

08:26AM EDT Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $270 Benzinga

Oct 6, 2020

07:10AM EDT BioAtla And BeiGene Revise Global Development And Commercialization Agreement For Novel Conditionally Active Biologic CTLA-4 Candidate BA3071; Previous Agreement From April 2019 Now Becomes A Global Licensing Agreement For BA3071 Benzinga

Sep 21, 2020

07:09AM EDT Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer Benzinga

07:06AM EDT Leap Therapeutics And BeiGene Says First Patient Dosed In DisTinGuish Study RTTNews

07:01AM EDT in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer PR Newswire

Sep 9, 2020

07:16AM EDT BeiGene Announces Acceptance And Priority Review By Health Canada Of New Drug Submission For BRUKINSA In Waldenstrm's Macroglobulinemia Benzinga

Sep 4, 2020

09:19AM EDT BeiGene Announces Inclusion Of Shares In Shanghai-Hong Kong, Shenzhen-Hong Kong Stock Connect Programs Benzinga

Aug 27, 2020

07:02AM EDT BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals Benzinga

Aug 24, 2020

02:48PM EDT BeiGene Receives FDA Orphan Drug Designation For Zanubrutinib Benzinga

08:21AM EDT BeiGene to Commercialize Bio-Thera Solutions' BAT1706 in China, BeiGene Makes Upfront Payment Benzinga

Aug 10, 2020

08:43AM EDT Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $241 Benzinga

Aug 6, 2020

05:10PM EDT BeiGene Q2 ADS $(4.31) Down From $(1.43) YoY, Sales $65.64M Down From $243.35M YoY Benzinga

Aug 5, 2020

07:00AM EDT BeiGene Announces Data on Tislelizumab and Pamiparib to Be GlobeNewswire Inc

Jul 27, 2020

09:22AM EDT BeiGene Says Priority Review Granted To NDA Of Pamiparib In Ovarian Cancer In China RTTNews

09:15AM EDT Priority Review Granted to BeiGenes New Drug GlobeNewswire Inc

Jul 20, 2020

06:39AM EDT Assembly Biosciences Grants BeiGene Rights to Develop and Commercialize its Clinical-Stage Inhibitors for Hepatitis B in China, Assembly to Recieve $40M Cash Upfront and Up to $500M in Additional Payments Benzinga

06:30AM EDT -- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China --- Assembly receives $40 million upfront payment and is eligible to receiveup to $500 million in potential development, regulatory, and sales milestone payments plus royalties on product sales --- Assembly to host webcast and conference call today at 8:30 am ET -- GlobeNewswire Inc

Jul 17, 2020

09:06AM EDT BeiGene Announces Acceptance Of New Drug Application Of Pamiparib In Ovarian Cancer In China Benzinga

09:03AM EDT BeiGene Reports Acceptance Of NDA Of Pamiparib In Ovarian Cancer In China RTTNews

09:00AM EDT BeiGene Announces Acceptance of a New Drug Application of GlobeNewswire Inc

Jul 15, 2020

05:00PM EDT BeiGene Announces Closing of Approximately $2.08 Billion GlobeNewswire Inc

09:51AM EDT Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $235 Benzinga

Jul 13, 2020

10:51AM EDT Why BeiGene's Stock Is Trading Higher Today Benzinga

10:17AM EDT Shares of Chinese biotechnology company BeiGene, Ltd. (BGNE) are climbing more than 8% Monday morning to hit a new high of $215.85. RTTNews

06:00AM EDT A Peek Into The Markets: US Stock Futures Gain; PepsiCo Earnings In Focus Benzinga

05:32AM EDT Amgen Announces $421M Investment In BeiGene Benzinga

Jul 12, 2020

10:44PM EDT Amgen (AMGN) said it will additionally invest about $421 million in Chinese biotech company BeiGene's (BGNE) registered direct offering of ordinary shares. The investment maintains Amgen's current pro rata ownership of BeiGene at about 20.3%. RTTNews

09:52PM EDT BeiGene Ltd. (BGNE) announced the pricing of a registered direct offering of 145.84 million ordinary shares, par value $0.0001 per share, to certain existing investors. RTTNews

08:28PM EDT BeiGene Prices 145.8M Share Registered Direct Offering @$14.23/Share; $185/ADS Benzinga

08:27PM EDT BeiGene Prices 145.8M Share Registered Direct Offering @$14.23/Share Benzinga

08:00PM EDT BeiGene Announces Pricing of Approximately $2.08 Billion GlobeNewswire Inc

Share